Latest Gefitinib Stories
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
DelMar Pharmaceuticals Presents Data at AACR's New Horizons in Cancer Research Conference in Shanghai, China VANCOUVER, British Columbia, MENLO PARK, Calif. and SHANGHAI, Oct.
- LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing
- AbbVie presents preliminary data from randomized phase 2 trial of veliparib in non-small cell lung cancer NORTH CHICAGO, Ill., Sept.
Introduction of Extended RAS Testing and Recent Clinical Trial Data Will Affect How Physicians Treat Colorectal Cancer Patients, According to Findings from Decision Resources Group BURLINGTON,
HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data
LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- 7 total abstracts accepted for afatinib and other compounds from the company's oncology research program RIDGEFIELD, Conn., May 30, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced
-- Results from two Phase III studies (LUX-Lung 3 and LUX-Lung 6) add to the body of evidence supporting the importance of first-line treatment with afatinib in patients whose tumors express the EGFR
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.